Intravitreal injection of crystalline triamcinolone acetonide in the treatment of diffuse diabetic macular oedema

被引:21
|
作者
Jonas, JB [1 ]
Degenring, R [1 ]
机构
[1] Univ Heidelberg, Augenklin, Fak Klin Med Mannheim, D-68167 Mannheim, Germany
关键词
diabetic maculopathy; diabetic retinopathy; intraocular pressure; macular; oedema; triamcinolone acetonide;
D O I
10.1055/s-2002-32884
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background: To evaluate the clinical outcome of an intravitreal injection of crystalline triamcinolone acetonide as treatment of clinically significant diffuse diabetic macular oedema. Patients and methods: The study included 8 patients (10 eyes) who received an intravitreal injection of 25 mg crystalline triamcinolone acetonide as treatment of clinically significant diffuse diabetic macular oedema follow-up time was 3.48 +/- 3.25 months (mean +/- SD). The study group was compared with a control group of 16 patients with diffuse diabetic macular oedema who underwent grid laser coagulation of the macular region. Results: In the study group, visual acuity increased significantly (p = 0.03) from 0.11 +/- 0.09 at baseline of the study to a maximum of 0.19 +/- 0.13 during the follow-up period. Six (85.7%) of the seven eyes with a follow-up period of more than 4 weeks gained in visual acuity. Towards the end of the follow-up period, the triamcinolone acetonide crystals completely resolved and visual acuity decreased to 0.15 +/- 0.11, which was higher, but not significantly (p=0.14) higher than the baseline value. Visual acuity was significantly (p < 0.05) higher in the study group than in the control group for the examinations obtained up to 12 weeks after the injection. Conclusions: Intravitreal injection of 25 mg crystalline triamcinolone acetonide may be beneficial for temporarily increasing visual acuity in patients with clinically significant diffuse diabetic macular oedema.
引用
收藏
页码:429 / 432
页数:4
相关论文
共 50 条
  • [1] Repeated intravitreal injection of triamcinolone acetonide for diffuse diabetic macular oedema
    Jonas, JB
    Kreissig, I
    Degenring, RF
    Kamppeter, BA
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2005, 89 (01) : 122 - 122
  • [2] Intravitreal triamcinolone acetonide for the treatment of diffuse diabetic macular oedema - A case report
    Wang, CG
    Katz, BJ
    Turner, MJ
    Hu, JB
    Zhang, K
    ANNALS ACADEMY OF MEDICINE SINGAPORE, 2006, 35 (02) : 112 - 114
  • [3] Diffuse diabetic macular oedema treated with intravitreal bevacizumab or triamcinolone acetonide
    Rensch, Florian
    Spandau, Ulrich H. M.
    Wickenhaeuser, Anne
    Jonas, Jost B.
    ACTA OPHTHALMOLOGICA, 2010, 88 (02) : e36 - e37
  • [4] Macular function after intravitreal triamcinolone acetonide injection for diabetic macular oedema
    Karacorlu, Murat
    Ozdemir, Hakan
    Senturk, Fevzi
    Karacorlu, Serra Arf
    Uysal, Omer
    ACTA OPHTHALMOLOGICA, 2010, 88 (05) : 558 - 563
  • [5] Comparison of a single intravitreal injection of bevacizumab versus triamcinolone acetonide as primary treatment for diffuse diabetic macular oedema
    Penha, Fernando Marcondes
    Maia, Mauricio
    Cardillo, Jose Augusto
    Fernando Arevalo, J.
    Wu, Lihteh
    Rodriguez, Francisco J.
    Berrocal, Maria H.
    Farah, Michel Eid
    ACTA OPHTHALMOLOGICA, 2012, 90 (02) : e160 - e161
  • [6] Intravitreal triamcinolone injection for chronic diffuse diabetic macular oedema
    Avci, R
    Kaderli, B
    Akalp, FD
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2006, 34 (01): : 27 - 32
  • [7] Intravitreal triamcinolone acetonide for refractory diabetic macular oedema
    Fernando, AI
    Pandit, JC
    JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 2005, 98 (09) : 421 - 422
  • [8] Intravitreal triamcinolone for diffuse diabetic macular oedema
    S K Gibran
    A Cullinane
    S Jungkim
    P E Cleary
    Eye, 2006, 20 : 720 - 724
  • [9] Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema
    Sheth, Saumil
    Rush, Ryan
    Natarajan, Sundaram
    Gillies, Mark
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2011, 39 (07): : 673 - 681
  • [10] Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema
    Spandau, UHM
    Derse, M
    Schmitz-Valckenberg, P
    Papoulis, C
    Jonas, JB
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2005, 89 (08) : 999 - 1003